GlassScriptPhysician profile
Mary Elmquist
NPI 1770766453
$4,786.91
in general payments reported to CMS, 2019-2025
36 companies · $2,583 in 2025
The $2,583 reported for 2025 was more than what 96% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $408 · 2022: $467 · 2023: $576 · 2024: $753 · 2025: $2,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,300 · Travel and Lodging: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,300.16 |
| Travel and Lodging | $612.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $612.17 | 2025 | Percept PC Brainsense |
| Viiv Healthcare Company | $541.14 | 2022-2025 | Dovato, Cabenuva |
| Abbvie INC. | $516.22 | 2021-2025 | |
| Abbott Laboratories | $398.35 | 2021-2024 | Jeti Peripheral Catheter, Optis, Xience Sierra |
| Eisai INC. | $393.23 | 2023-2025 | |
| Gilead Sciences, INC. | $237.19 | 2022-2025 | Biktarvy |
| Lilly USA, LLC | $227.47 | 2022-2025 | Kisunla, Zepbound |
| Ucb, INC. | $174.23 | 2024-2025 | Nayzilam, Fintepla, Briviact |
| Merck Sharp & Dohme LLC | $166.82 | 2021-2025 | Pifeltro, Capvaxive, Delstrigo |
| Mylan Specialty L.P. | $150.70 | 2021-2023 | Yupelri |
| Melinta Therapeutics, LLC | $138.27 | 2024-2025 | Rezzayo, Kimyrsa |
| Ferring Pharmaceuticals INC. | $125.00 | 2023 | Rebyota |
| Emd Serono, INC. | $124.99 | 2024 | Mavenclad |
| Exact Sciences Corporation | $111.06 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $103.08 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $89.65 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $67.21 | 2022-2023 | Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.99 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.68 | 2022-2023 | |
| Lundbeck LLC | $49.40 | 2023-2024 | Rexulti |
| Biogen, INC. | $48.80 | 2025 | Vumerity |
| Merz Pharmaceuticals, LLC | $38.89 | 2025 | Xeomin |
| Phathom Pharmaceuticals, INC. | $35.56 | 2024-2025 | Voquezna |
| Jazz Pharmaceuticals INC. | $34.06 | 2025 | |
| Insmed, INC. | $33.74 | 2025 | Arikayce |
| Novo Nordisk INC | $33.15 | 2025 | Rybelsus, Ozempic |
| Neurocrine Biosciences, INC. | $27.97 | 2025 | |
| Axsome Therapeutics, INC. | $27.20 | 2025 | Symbravo |
| Argenx US, INC. | $25.60 | 2025 | Vyvgart Hytrulo |
| Sanofi Pasteur INC. | $25.31 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.26 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $21.75 | 2025 | Dupixent |
| Paratek Pharmaceuticals, INC. | $20.99 | 2025 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $17.95 | 2025 | |
| Amgen INC. | $16.07 | 2025 | Uplizna |
| Baxter Healthcare | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Elmquist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.